I
Inhee Choi
Researcher at Institut Pasteur Korea
Publications - 42
Citations - 1772
Inhee Choi is an academic researcher from Institut Pasteur Korea. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 12, co-authored 35 publications receiving 1204 citations.
Papers
More filters
Journal ArticleDOI
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Sangeun Jeon,Meehyun Ko,Jihye Lee,Inhee Choi,Soo Young Byun,Soonju Park,David Shum,Seungtaek Kim +7 more
TL;DR: 24 potential antiviral drug candidates against SARS-CoV-2 infection are identified and two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects.
Journal ArticleDOI
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
Kevin Pethe,Pablo Bifani,Jichan Jang,Sunhee Kang,Seijin Park,Sujin Ahn,Jan Jiricek,Ju-Young Jung,Hee Kyoung Jeon,Jonathan Cechetto,Thierry Christophe,Honggun Lee,Marie Kempf,Mary Jackson,Anne J. Lenaerts,Hang Ohuong Pham,Victoria Jones,Min Jung Seo,Young-Mi Kim,Mooyoung Seo,Jeong Jea Seo,Dongsik Park,Yoonae Ko,Inhee Choi,Ryangyeo Kim,Se Yeon Kim,Seungbin Lim,Seung-Ae Yim,Jiyoun Nam,Hwankyu Kang,Haejin Kwon,Chun-Taek Oh,Yoojin Cho,Yunhee Jang,Junghwan Kim,Adeline C. Y. Chua,Bee Huat Tan,Mahesh Nanjundappa,Srinivasa P. S. Rao,Whitney Barnes,René Wintjens,John R. Walker,Sylvie Alonso,Saeyeon Lee,Jungjun Kim,Soohyun Oh,Taegwon Oh,Ulf Nehrbass,Sung-Jun Han,Zaesung No,Jinhwa Lee,Priscille Brodin,Sang Nae Cho,Kiyean Nam,Jaeseung Kim +54 more
TL;DR: The optimized IPA compound Q203 inhibited the growth of MDR and XDR M. tuberculosis clinical isolates in culture broth medium in the low nanomolar range and was efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body weight, which highlights the potency of this compound.
Posted ContentDOI
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
Sangeun Jeon,Meehyun Ko,Jihye Lee,Inhee Choi,Soo Young Byun,Soonju Park,David Shum,Seungtaek Kim +7 more
TL;DR: A panel of 48 FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS -CoV-2 infection, and a total of 24 drugs which exhibited antiviral efficacy were found.
Journal ArticleDOI
Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent
Sunhee Kang,Ryang Yeo Kim,Min Jung Seo,Saeyeon Lee,Young-Mi Kim,Mooyoung Seo,Jeong Jea Seo,Yoonae Ko,Inhee Choi,Jichan Jang,Jiyoun Nam,Seijin Park,Hwankyu Kang,Hyungjun Kim,Jungjun Kim,Sujin Ahn,Kevin Pethe,Kiyean Nam,Zaesung No,Jaeseung Kim +19 more
TL;DR: It is found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv and the optimized IPAs 49 and 50 showed not only excellent oral bioavailability but also displayed significant colony-forming unit (CFU) reduction in mouse lung.
Posted ContentDOI
Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19
Meehyun Ko,So Young Chang,Soo Young Byun,Inhee Choi,Anne Laure Pham Hung d'Alexandry d'Orengiani,David Shum,Ji-Young Min,Marc P. Windisch +7 more
TL;DR: The results identify potential therapeutic options for MERS-CoV infections, and provide a basis to treat coronavirus disease 2019 (COVID-19) and other coronav virus-related illnesses.